MARY CROWLEY NEWSLETTER: VOLUME 10, ISSUE 4
EXPANDING THERAPIES FOR PROSTATE CANCER
The prostate is a hormonally regulated organ and prostate cancer is reliant on androgen receptor signaling for growth. The treatment of advanced prostate cancer has thus traditionally focused on the inhibition of androgen signaling.
NEW TRIALS AT MARY CROWLEY CANCER RESEARCH
The treatment of advanced prostate cancer has thus traditionally focused on the inhibition of androgen signaling (for example through blockade of the androgen receptor, or inhibition of testosterone production).
MARY CROWLEY NEWSLETTER: VOLUME 10, ISSUE 3
EFFECTS OF ROVALPITUZUMAB TESIRINE ON VENTRICULAR REPOLARIZATION IN PATIENTS WITH SMALL-CELL LUNG CANCER
Small cell lung cancer (SCLC) is a leading cause of cancer death worldwide, with few treatment options. Rovalpituzumab tesirine (Rova-T) is an antibody-drug conjugate that targets delta-like 3 on SCLC cells to deliver a…
ENTRECTINIB IN PATIENTS WITH ADVANCED OR METASTATIC NTRK FUSION-POSITIVE SOLID TUMOURS: INTEGRATED ANALYSIS OF THREE PHASE 1–2 TRIALS
Entrectinib is a potent inhibitor of tropomyosin receptor kinase (TRK) A, B, and C, which has been shown to have anti-tumour activity against NTRK gene fusion-positive solid tumours, including…
LONG-TERM FOLLOW-UP OF PHASE 2A TRIAL RESULTS INVOLVING ADVANCED OVARIAN CANCER PATIENTS TREATED WITH VIGIL® IN FRONTLINE MAINTENANCE
MARY CROWLEY NEWSLETTER: VOLUME 10, ISSUE 2
A MESSAGE FROM CHAIRMAN OF THE BOARD ROY LAMKIN
The health and safety of the patients at Mary Crowley Cancer Research is always our top priority.